The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC
Videos  >  

Indoximod as an Active IDO Pathway Inhibitor in Melanoma

Yousef Zakharia, MD
Published Online:7:46 PM, Thu May 11, 2017

Yousef Zakharia, MD, assistant professor, University of Iowa, Holden Comprehensive Cancer Center, discusses indoximod as an active IDO inhibitor in advanced melanoma. Zakharia gives an overview of findings from a phase II clinical trial which investigated indoximod in combination with pembrolizumab (Keytruda) for these patients.
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.